TY - JOUR
T1 - The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
AU - Tamborero, David
AU - Dienstmann, Rodrigo
AU - Rachid, Maan Haj
AU - Boekel, Jorrit
AU - Lopez-Fernandez, Adria
AU - Jonsson, Markus
AU - Razzak, Ali
AU - Braña, Irene
AU - De Petris, Luigi
AU - Yachnin, Jeffrey
AU - Baird, Richard
AU - Loriot, Yohann
AU - Massard, Christophe
AU - Martin-Romano, Patricia
AU - Opdam, Frans
AU - Schlenk, Richard F.
AU - Vernieri, Claudio
AU - Masucci, Michele
AU - Villalobos, Xenia
AU - Chavarria, Elena
AU - Anand, Shubha
AU - Baars, Danny
AU - Bajalica-Lagercrantz, Svetlana
AU - Baird, Richard
AU - Bierkens, Mariska
AU - Blomqvist, Lennart
AU - Bono, Costanza
AU - De Petris, Luigi
AU - Doherty, Gary J.
AU - Forest, Arnauld
AU - Fornerone, Valentina
AU - Gabaldi, Paola
AU - Haglund, Felix
AU - Hartman, Johan
AU - Horak, Peter
AU - Jutzi, Tanja
AU - Kasanicki, Mary
AU - Kreutzfeldt, Simon
AU - Le Cornet, Lucian
AU - Lewensohn, Rolf
AU - Lindberg, Johan
AU - Lopez, Carlos
AU - Lundqvist, Andreas
AU - Martin, Jose Ezequiel
AU - Meijer, Gerrit
AU - Muñoz, Susana
AU - Camus, Maud Ngo
AU - Nicotra, Claudio
AU - Nuciforo, Paolo
AU - Voest, Emile
N1 - Funding Information:
We acknowledge the Ensembl team at EMBL-EBI and W. Zhou for the development and support of the Ensembl Variant Effect Predictor and TransVar tools, respectively; the IT department at SciLifeLab for their technical support in deploying the portal; the developers and curators of publicly available knowledge bases for their work in these resources; the OncoKB team for facilitating the use of their web API in the public-MTBP website; and H. Zhang for technical support. The project has received support from the Personalized Cancer Medicine program at Karolinska funded by The Cancer Research Funds of Radiumhemmet, Swedish Foundation of Strategic Research (principal investigator, J.L.), Stockholm County Council (ALF funding, principal investigator, J.L.), from Cancer Research UK in the Cambridge Centre, from the CaixaResearch Advanced Oncology Research Program supported by ”la Caixa” Foundation, and from the European Union’s Horizon 2020 research and innovation program under grant agreement 965397 (CCE_DART). We also acknowledge F. Hoffmann-La Roche for their support in the Basket of Baskets trial (NCT03767075).
Funding Information:
We acknowledge the Ensembl team at EMBL-EBI and W. Zhou for the development and support of the Ensembl Variant Effect Predictor and TransVar tools, respectively; the IT department at SciLifeLab for their technical support in deploying the portal; the developers and curators of publicly available knowledge bases for their work in these resources; the OncoKB team for facilitating the use of their web API in the public-MTBP website; and H. Zhang for technical support. The project has received support from the Personalized Cancer Medicine program at Karolinska funded by The Cancer Research Funds of Radiumhemmet, Swedish Foundation of Strategic Research (principal investigator, J.L.), Stockholm County Council (ALF funding, principal investigator, J.L.), from Cancer Research UK in the Cambridge Centre, from the CaixaResearch Advanced Oncology Research Program supported by ”la Caixa” Foundation, and from the European Union’s Horizon 2020 research and innovation program under grant agreement 965397 (CCE_DART). We also acknowledge F. Hoffmann-La Roche for their support in the Basket of Baskets trial (NCT03767075).
Publisher Copyright:
© 2022, The Author(s).
© 2022. The Author(s).
PY - 2022/2
Y1 - 2022/2
N2 - There is a growing need for systems that efficiently support the work of medical teams at the precision-oncology point of care. Here, we present the implementation of the Molecular Tumor Board Portal (MTBP), an academic clinical decision support system developed under the umbrella of Cancer Core Europe that creates a unified legal, scientific and technological platform to share and harness next-generation sequencing data. Automating the interpretation and reporting of sequencing results decrease the need for time-consuming manual procedures that are prone to errors. The adoption of an expert-agreed process to systematically link tumor molecular profiles with clinical actions promotes consistent decision-making and structured data capture across the connected centers. The use of information-rich patient reports with interactive content facilitates collaborative discussion of complex cases during virtual molecular tumor board meetings. Overall, streamlined digital systems like the MTBP are crucial to better address the challenges brought by precision oncology and accelerate the use of emerging biomarkers.
AB - There is a growing need for systems that efficiently support the work of medical teams at the precision-oncology point of care. Here, we present the implementation of the Molecular Tumor Board Portal (MTBP), an academic clinical decision support system developed under the umbrella of Cancer Core Europe that creates a unified legal, scientific and technological platform to share and harness next-generation sequencing data. Automating the interpretation and reporting of sequencing results decrease the need for time-consuming manual procedures that are prone to errors. The adoption of an expert-agreed process to systematically link tumor molecular profiles with clinical actions promotes consistent decision-making and structured data capture across the connected centers. The use of information-rich patient reports with interactive content facilitates collaborative discussion of complex cases during virtual molecular tumor board meetings. Overall, streamlined digital systems like the MTBP are crucial to better address the challenges brought by precision oncology and accelerate the use of emerging biomarkers.
KW - Decision Support Systems, Clinical
KW - High-Throughput Nucleotide Sequencing/methods
KW - Humans
KW - Medical Oncology/methods
KW - Neoplasms/diagnosis
KW - Precision Medicine/methods
UR - http://www.scopus.com/inward/record.url?scp=85128488411&partnerID=8YFLogxK
U2 - 10.1038/s43018-022-00332-x
DO - 10.1038/s43018-022-00332-x
M3 - Article
C2 - 35221333
AN - SCOPUS:85128488411
VL - 3
SP - 251
EP - 261
JO - Nature Cancer
JF - Nature Cancer
IS - 2
ER -